Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

Kymera Therapeutics raises $250.8M in public offering to advance its innovative degrader medicines for immunological diseases.

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the ...

The rapid adoption of the Omnipod 5 answered a question automated insulin delivery system manufacturers posed for years: with ...

In multiple sclerosis (MS), an alteration of neuronal metabolism caused by dysfunction of its proteasome, the cellular machinery responsible for recycling proteins, contributes to neurodegeneration in ...

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” first quarter 2025 ...

Trafficking and exploitation can be a blind spot for business leaders, putting employees at risk and exposing the ...